Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations

Using genome-wide expression profiles of a prospective training cohort of breast cancer patients, ClinicoMolecular Triad Classification (CMTC) was recently developed to classify breast cancers into three clinically relevant groups to aid treatment decisions. CMTC was found to be both prognostic and predictive in a large external breast cancer cohort in that study. This study serves to validate the reproducibility of CMTC and its prognostic value using independent patient cohorts. An independent internal cohort (n = 284) and a new external cohort (n = 2,181) were used to validate the association of CMTC between clinicopathological factors, 12 known gene signatures, two molecular subtype classifiers, and 19 oncogenic signalling pathway activities, and to reproduce the abilities of CMTC to predict clinical outcomes of breast cancer. In addition, we also updated the outcome data of the original training cohort (n = 147). The original training cohort reached a statistically significant difference (p < 0.05) in disease-free survivals between the three CMTC groups after an additional two years of follow-up (median = 55 months). The prognostic value of the triad classification was reproduced in the second independent internal cohort and the new external validation cohort. CMTC achieved even higher prognostic significance when all available patients were analyzed (n = 4,851). Oncogenic pathways Myc, E2F1, Ras and β-catenin were again implicated in the high-risk groups. Both prospective internal cohorts and the independent external cohorts reproduced the triad classification of CMTC and its prognostic significance. CMTC is an independent prognostic predictor, and it outperformed 12 other known prognostic gene signatures, molecular subtype classifications, and all other standard prognostic clinicopathological factors. Our results support further development of CMTC portfolio into a guide for personalized breast cancer treatments.

• Publication year

  2014

• Venue

  Breast Cancer Research

• Publication date

  2014-07-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/bcr3686PMID 24996446PMCID 4226941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene Expression Omnibus (GEO)

  2013cited by this paper
• Practical implications of gene-expression-based assays for breast oncologists

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.

  2011cited by this paper
• Gene expression profiling in breast cancer: classification, prognostication, and prediction.

  2011cited by this paper
• A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis

  2011influential reference
• Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

  2011cited by this paper
• A pathway-based classification of human breast cancer

  2010cited by this paper
• Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• The humoral immune system has a key prognostic impact in node-negative breast cancer.

  2008cited by this paper
• An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors

  2008cited by this paper
• Stromal gene expression predicts clinical outcome in breast cancer

  2008influential reference
• The prognostic role of a gene signature from tumorigenic breast-cancer cells.

  2007cited by this paper
• The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy

  2007cited by this paper
• Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.

  2006cited by this paper
• Oncogenic pathway signatures in human cancers as a guide to targeted therapies

  2006cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005influential reference
• Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002influential reference
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper

• Copper ionophore enhanced cisplatin efficiency through DLAT-cuprotosis.

  2025cites this paper
• Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients

  2023cites this paper
• Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis

  2020cites this paper
• Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer

  2019cites this paper
• Anticancer polymers designed for killing dormant prostate cancer cells

  2019cites this paper
• Applications of Microarray in Cancer Cell Signaling Pathways

  2019cites this paper
• Defining common principles of gene co-expression refines molecular stratification in cancer

  2018cites this paper
• 1 A homeobox protein , NKX 6 . 1 , upregulates interleukin-6 expression for cell growth in basal-like breast cancer cells

  2018cites this paper
• Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer

  2017cites this paper
• A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells.

  2016cites this paper